In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice

Neuroscience Letters

Volumn 463, Issue 3, 2009, Pages 215-218

  Luthra, Pratibha Mehta ^a   Prakash, Amresh ^a   Barodia, Sandeep Kumar ^a   Kumari, Rita ^a   Mishra, Chandra Bhushan ^a   Kumar, J B Senthil ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

A2AR; Auto dock; GPCR; HAL; NATA; Parkinson's disease

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A2A RECEPTOR; CAFFEINE; DOPAMINE; HALOPERIDOL; NAPHTHA[1,2 D]THIAZOL 2 AMINE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; COMPUTER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; CORPUS STRIATUM; DOPAMINE; HALOPERIDOL; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; MOVEMENT DISORDERS; NAPHTHALENES; RECEPTOR, ADENOSINE A2A; THIAZOLES; TRIAZOLES;

EID: 68949216948     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.07.085     Document Type: Article

References (37)

1. Accelrys Inc. ForceField-Based Simulations (2002), Accelrys, Inc., San Diego. http://www.accelrys.com/doc/life/insight2000.1/ffbs/FF_SimulTOC.html
2. Accelrys Inc., Homology/Insight-II, San Diego, USA, 1999. http://www.accelrys.com/doc/pdf/homology2K.pdf.
3. Alexander S.P.H., and Peters J.A. Receptor & ion channel nomenclature supplement. Trends Pharmacol. Sci. 19 (1998) 1-85
4. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., and Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
5. Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., and Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50 (2001) 56-63
6. 2AR adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J. Med. Chem. 45 (2002) 115-126
7. 3 adenosine receptor antagonists. Eur. J. Med. Chem. 38 (2003) 367-382
8. Brady G.P., and Stouten P.F.W. Fast prediction and visualization of protein binding pockets with PASS. J. Comput. Aided Mol. Des. 14 (2000) 383-401
9. Corsi C., Melani A., Bianchi L., Pepeu G., and Pedata F. Effect of adenosine A2A receptor stimulation on GABA release from the striatum of young and aged rats in vivo. Neuroreport 16 (1999) 3933-3937
10. 2A receptors. J. Neurochem. 78 (2001) 183-198
11. DeLano W.L. PyMOL Reference Manual (2003), DeLano Scientific LLC, San Carlos, CA
12. Discover 3 User Guide, MSI, San Diego, USA, 1999.
13. Ferré S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 (1997) 482-487
14. 2AR receptors. Eur. J. Pharmacol. 380 (1999) 197-202
15. Fuxe K., Ferré S., Zoli M., and Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev. 26 (1998) 258-273
16. Gasteiger J., and Marsili M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36 (1980) 3219-3228
17. Gerfen C.R. The neostriatal mosaic levels of compartmental organization. Trends Neurosci. 15 (1992) 33-139
18. Gines S., Hillion J., Torvinen M., Le Crom S., Casado V., Canela E.I., Rondin S., Lew J.Y., Watson S., and Zoli M. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8606-8611
19. 2A receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 47 (2004) 414-426
20. Hattori K., Uchino S., Isosaka T., Maekawa M., Iyo M., Sato T., Kohsaka S., Yagi T., and Yuasa S. Fyn is required for HAL-induced catalepsy in mice. J. Biol. Chem. 281 (2006) 7129-7135
21. 2AR receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80 (2002) 262-270
22. 2AR adenosine receptor. Dokl. Biochem. Biophys. 389 (2003) 94-97
23. 2A adenosine receptor crystallographic structure. J. Med. Chem. 52 (2009) 3284-3292
24. 2AR adenosine receptor bound to an antagonist. Science 322 (2008) 1211-1217
25. Jaskiw G.E., and Bongiovanni R. Brain tyrosine depletion attenuates HAL-induced striatal dopamine release in vivo and augments HAL-induced catalepsy in the rat. Psychopharmacology (Berl) 172 (2004) 100-107
26. 2A agonists and antagonists. J. Med. Chem. 46 (2003) 4847-4859
27. Laskoswki R.A., MacArthur M.W., Moss D.S., and Thorton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
28. Luthra P.M., Barodia S.K., and Raghubir R. Antagonism of HAL-induced swim impairment in l-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. J. Neurosci. Methods 178 (2009) 284-290
29. Mehra S.C., and Zaman S. Synthesis of some local anesthetics from 2-amino naphthothiazole. J. Chem. Eng. Data 23 (1978) 89-90
30. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
31. Muijlwijk-Koezen J.E.V., Timmerman H., Vollinga R.C., Künzel J.F.V.D., Groote M., Visser S., and Ijzerman A.P. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J. Med. Chem. 44 (2001) 749-762
32. 2AR-selective adenosine receptor antagonists. J. Med. Chem. 40 (1997) 4396-4405
33. Ohlmeyer M.H.J., Swanson R.N., Dillard L., Reader J.C., Asouline G., Kobayishi R., Wigler M., and Still W.C. Complex synthetic chemical libraries indexed with molecular tags. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10922-10926
34. Schwarzschild M.A., Chen J.F., and Ascherio A. Caffeinated clues and the promise of adenosine A (2A) antagonists in PD. Neurology 58 (2002) 1154-1160
35. Svenningsson P., Le Moine C., Fisone G., and Fredholm B.B. Distribution, biochemistry and function of striatal A2ARs. Prog. Neurobiol. 59 (1999) 355-396
36. 2B adenosine receptor antagonists. J. Chem. Inf. Model. 47 (2007) 613-625
37. 2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276 (1996) 398-404